Table 3.

Center-level empirical Bayes estimates adjusted for case-level characteristics. ^*

Immunosuppression regimen (Reference: IL2rAb)	No. of centers in pairwise comparison	No. of centers significantly above reference probability	No. of centers significantly below reference probability
Thymoglobulin	253	105 (43.2%)	116 (44.7%)
Alemtuzumab	123	51 (38.7%)	52 (10.5%)
Other	132	40 (32.0%)	38 (19.5%)
No induction	256	89 (35.7%)	115 (43.2%)

^*Constructed from pairwise comparisons of regimen of interest versus reference regimen (IL2rAb).

IL2rAb, interleukin-2 receptor blocking antibodies.